Catabasis Pharmaceuticals Inc.
Catabasis Pharmaceuticals Inc. is listed today as Catabasis Pharmaceuticals: market value, financials and filings are on its company page.
Funding rounds
5 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2021 | $110 M | No. 5 | $50 to $250 million | equity | SEC | |
| Jan 2021 | $176 M | Issued in a merger or acquisition | $50 to $250 million | equity, options | SEC | |
| Mar 2015 | $12 M | No. 4 | $10 to $50 million | equity | SEC | |
| Oct 2013 | $32 M | No. 3 | $10 to $50 million | equity | SEC | |
| Jan 2013 | $9 M | No. 2 | $2 to $10 million | equity | SEC | |
| Apr 2010 | $8 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Catabasis Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).
SEC Form D · Feb 2021
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Feb 2021
That is all the official record says: Catabasis Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Catabasis Pharmaceuticals Inc. are on record.
Investors#
18 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Advanced Technology Ventures VIII LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| ATV Associates VIII, L.L.C. | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Clarus Lifesciences II, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Clarus Ventures II GP, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Clarus Ventures II, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Jill C. Milne | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Joanne M. Donovan | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2015) | SEC Form 3 |
| MedImmune Ventures, Inc. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Michael Jirousek | Person | not stated | not stated | Held Series A and B preferred stock (Form 3, 2015) | SEC Form 3 |
| Perceptive Advisors LLC | Fund or asset manager | not stated | not stated | Held Series X preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Perceptive Life Sciences Master Fund LTD | Fund or asset manager | not stated | not stated | Held Series X preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Perceptive Xontogeny Venture Fund, LP | Venture capital | not stated | not stated | Held Series X preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Rick Modi | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2015) | SEC Form 3 |
| SV Life Sciences Fund V (GP), LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| SV Life Sciences Fund V LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| SV Life Sciences Fund V Strategic Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Svlsf V, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Xontogeny, LLC | Other | not stated | not stated | Held Series X preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 23 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew C. Komjathy | Executive officer | Feb 2021 |
| Andrew C. Nichols | Executive officer | Feb 2021 |
| Ben T. Harshbarger | Executive officer | Feb 2021 |
| Jill C. Milne | Executive officer | Feb 2021 |
| Joanne C. Donovan | Executive officer | Feb 2021 |
| Noah T. Clauser | Executive officer | Feb 2021 |
| Ian C. Sanderson | Executive officer | Mar 2015 |
| Jill Milne | Executive officer | Nov 2013 |
| Michael Jirousek | Executive officer | Nov 2013 |
| Fred T. Callori | Director | Feb 2021 |
| Gregg T. Lapointe | Director | Feb 2021 |
| Hugh T. Cole | Director | Feb 2021 |
| Jill C. Milne | Director | Feb 2021 |
| Joanne T. Beck | Director | Feb 2021 |
| Jonathan T. Violin | Director | Feb 2021 |
| Kenneth D. Bate | Director | Feb 2021 |
| Michael D. Kishbauch | Director | Feb 2021 |
| Jean C. George | Director | Mar 2015 |
| Kenneth C. Bate | Director | Mar 2015 |
| Michael C. Ross | Director | Mar 2015 |
| Nicholas C. Galakatos | Director | Mar 2015 |
| Ron C. Laufer | Director | Mar 2015 |
| Jill Milne | Director | Nov 2013 |
| Michael Ross | Director | Nov 2013 |
| Nicholas Galakatos | Director | Nov 2013 |
| Ron Laufer | Director | Nov 2013 |
| Jeffrey Leiden | Director | Apr 2010 |
| Maggie LeFlore | Director | Apr 2010 |
About
Company in Cambridge, United States.